Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data
1. Piper Sandler maintains Overweight rating for TEVA with a $30 price target. 2. Insights from a gastroenterologist indicate potential for TEVA's duvakitug in treating IBD. 3. Biomarkers are significant for predicting clinical responses in IBD treatments. 4. Analyst will monitor TEVA's updates at the upcoming ECCO meeting for further direction.